OPTINOSE INC. - COMMON STOCK

Optinose to Present at the Needham Virtual Healthcare Conference

04 أبريل 2024 15:01:00 بحسب Nasdaq GlobeNewswire

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

15 مارس 2024 14:34:50 بحسب Nasdaq GlobeNewswire

Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

07 مارس 2024 06:00:43 بحسب Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results

29 فبراير 2024 15:40:00 بحسب Nasdaq GlobeNewswire

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

18 يناير 2024 11:00:00 بحسب Nasdaq GlobeNewswire

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

06 ديسمبر 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

22 نوفمبر 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Optinose Reports Third Quarter 2023 Financial Results and Operational Updates

09 نوفمبر 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Optinose Announces Reporting Date for Third Quarter 2023 Financial Results

27 أكتوبر 2023 07:00:00 بحسب Nasdaq GlobeNewswire

Optinose to Present at the 2023 Cantor Global Healthcare Conference

22 سبتمبر 2023 08:01:00 بحسب Nasdaq GlobeNewswire

Optinose Reports Second Quarter 2023 Financial Results and Operational Updates

10 أغسطس 2023 06:00:00 بحسب Nasdaq GlobeNewswire

Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million

27 يوليو 2023 06:00:01 بحسب Nasdaq GlobeNewswire

Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

16 يونيو 2023 15:08:00 بحسب Nasdaq GlobeNewswire

Optinose to Present at the Jefferies Healthcare Conference

02 يونيو 2023 12:00:00 بحسب Nasdaq GlobeNewswire

Optinose Reports First Quarter 2023 Financial Results and Operational Updates

11 مايو 2023 06:00:18 بحسب Nasdaq GlobeNewswire

Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE

04 مايو 2023 06:00:01 بحسب Nasdaq GlobeNewswire

Optinose Announces Reporting Date for First Quarter 2023 Financial Results

01 مايو 2023 15:30:00 بحسب Nasdaq GlobeNewswire

Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

18 أبريل 2023 07:00:01 بحسب Nasdaq GlobeNewswire

Optinose to Present at the Needham Virtual Healthcare Conference

12 أبريل 2023 15:00:00 بحسب Nasdaq GlobeNewswire

Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

07 مارس 2023 06:00:56 بحسب Nasdaq GlobeNewswire